Intech Investment Management LLC Grows Stock Holdings in Acelyrin, Inc. (NASDAQ:SLRN)

Intech Investment Management LLC boosted its holdings in Acelyrin, Inc. (NASDAQ:SLRN) by 71.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 26,587 shares of the company’s stock after buying an additional 11,040 shares during the period. Intech Investment Management LLC’s holdings in Acelyrin were worth $83,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of SLRN. Franklin Resources Inc. boosted its stake in shares of Acelyrin by 36.9% in the third quarter. Franklin Resources Inc. now owns 128,591 shares of the company’s stock worth $634,000 after acquiring an additional 34,642 shares during the period. Virtu Financial LLC bought a new position in Acelyrin in the 3rd quarter worth approximately $50,000. Barclays PLC grew its holdings in Acelyrin by 208.8% during the 3rd quarter. Barclays PLC now owns 96,408 shares of the company’s stock valued at $475,000 after buying an additional 65,188 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Acelyrin by 30.8% during the third quarter. Geode Capital Management LLC now owns 1,651,614 shares of the company’s stock valued at $8,144,000 after buying an additional 388,631 shares during the last quarter. Finally, Public Employees Retirement System of Ohio lifted its holdings in shares of Acelyrin by 54.6% in the third quarter. Public Employees Retirement System of Ohio now owns 102,347 shares of the company’s stock worth $505,000 after buying an additional 36,154 shares in the last quarter. 87.31% of the stock is owned by institutional investors.

Insider Activity at Acelyrin

In related news, CEO Mina Kim sold 17,986 shares of Acelyrin stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $2.74, for a total value of $49,281.64. Following the completion of the sale, the chief executive officer now directly owns 671,753 shares in the company, valued at $1,840,603.22. This trade represents a 2.61 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 13.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

SLRN has been the subject of several research analyst reports. HC Wainwright cut their target price on shares of Acelyrin from $8.00 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday, January 7th. Citigroup cut their price objective on Acelyrin from $6.00 to $3.00 and set a “neutral” rating for the company in a research report on Tuesday, January 7th. Finally, Wells Fargo & Company decreased their target price on Acelyrin from $15.00 to $13.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $9.60.

Acelyrin Price Performance

NASDAQ:SLRN opened at $2.60 on Friday. The firm has a market cap of $261.85 million, a PE ratio of -1.06 and a beta of 1.27. The company has a 50-day moving average of $2.34 and a 200 day moving average of $3.75. Acelyrin, Inc. has a 1-year low of $1.85 and a 1-year high of $7.25.

Acelyrin (NASDAQ:SLRN) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.07. Sell-side analysts anticipate that Acelyrin, Inc. will post -2.53 EPS for the current fiscal year.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.